New release of groundbreaking treatment planning system RayStation provides major advances for proton PBS Monte Carlo with GPU
RaySearch Laboratories AB (publ) has launched the latest release of its widely adopted treatment planning system RayStation®*. The new features and capabilities include two major advances for proton therapy treatment, as well as improved ways of generating plans with machine learning in Plan Explorer and auto-navigated multi-criteria optimization, among others.
Proton PBS Monte-Carlo (p-MC) dose engine migrated to GPU and ocular proton planning are among the significant innovations of the latest release of RayStation from RaySearch.
Initial tests suggest that the new GPU p-MC dose engine is around 10 times faster than the current CPU-based p-MC algorithm. The physics algorithms of the GPU p-MC have not changed so the dosimetric results will match those of the now well established RayStation CPU p-MC dose engine. GPU p-MC will initially be offered to a select number of clinics ahead of the release of RayStation 10B in December 2020, which may see even further p-MC performance gains.
10A features the first version of proton ocular planning in RayStation. RayOcular supports planning for classic clip based, gaze angle, fixed beam eye treatments using 3D image data (CT/MR) as input for adapting the detailed parameterized eye model. Other key features of RayOcular include tumor modeling using fundus photos, radiograph handling, and an accurate pencil-beam dose engine.
Another significant enhancement is the ability to generate treatment plans with machine learning in the Plan Explorer module. The Plan Explorer automatically generates a large number of plans for combinations of treatment techniques and machines for a specific patient. It also provides efficient means to filter and browse among plan candidates to find the most desired one. The addition of machine learning optimization adds speed in plan generation and makes it possible for a clinic to tailor the automatic plan generation even further.
Additional improvements to the treatment planning system include auto-navigated multi-criteria optimization (MCO), automated collimator angle selection for conformal arcs to facilitate stereotactic planning, calculation and export of relative EPID response for pre-treatment quality assurance, and enhancements in beam modeling for both photons and electrons.
Johan Löf, founder and CEO, RaySearch, says: “RaySearch celebrated the tenth anniversary of our treatment planning system in 2019. RayStation is now installed at 622 cancer center in 39 countries. This latest release, featuring machine learning optimization in Plan Explorer and ocular proton planning, is the result of many hours of hard work and close collaboration across the research, development and machine learning teams at RaySearch and we are proud to see widespread implementation of such an innovative system.”
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
* Subject to regulatory clearance in some markets.
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59